SCHEMBL3011909

SCHEMBL3011909

Cc1ccc(F)cc1S(=O)(=O)C1CCN(c2nc(Cc3cc(F)cc(Cl)c3)cs2)CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.35
CTSS P25774 4/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
NAAA Q02083 4/20 0.34
TP53 P04637 2/20 0.34
MAPT P10636 2/20 0.34
GPR52 Q9Y2T5 1/20 0.33
MAPK1 P28482 1/20 0.33
LMNA P02545 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
DRD2 P14416 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
KCNH2 Q12809 1/20 0.33
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
RIPK1 Q13546 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3019125 0.97 KMT2A (0.36) KMT2ACTSSSMN1; SMN2NAAATP53
SCHEMBL3015041 0.94 NAAA (0.36) KMT2ACTSSSMN1; SMN2NAAAMAPT
SCHEMBL3012974 0.91 MAPT (0.38) KMT2ACTSSSMN1; SMN2NAAATP53
SCHEMBL3012230 0.90 CTSS (0.45) CTSSSMN1; SMN2NAAAMAPK1DRD2
SCHEMBL3016919 0.90 CTSS (0.37) CTSSSMN1; SMN2NAAAMAPK1LMNA
SCHEMBL3003779 0.89 NAAA (0.35) KMT2ACTSSSMN1; SMN2NAAAMAPK1
SCHEMBL3011944 0.89 SOS1 (0.37) KMT2ACTSSSMN1; SMN2NAAATP53
SCHEMBL3013479 0.88 CTSS (0.33) CTSSSMN1; SMN2GPR52MAPK1LMNA
SCHEMBL3016743 0.88 CTSS (0.36) KMT2ACTSSNAAAMAPK1LMNA
SCHEMBL3009006 0.88 SMN1; SMN2 (0.37) CTSSSMN1; SMN2NAAAMAPK1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KMT2A 2680/4885CTSS 106/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.